Rapid detecting of the genomic mutations of the multidrug-resistant Mycobacterium tuberculosis by polymerase chain reaction-single strand conformational polymorphism

Abstract

Abstract: Objective RpoB、KatG、rpsL genes mutation analysis of INH、RFP、SM resistance in isolates of M.tuberculosis (MTB) were undertaken by PCR single strand conformation poylymorphism (SSCP),and to evaluating the value of diagnosing resistance of MTB.Methods Detecting of INH、RFP、SM resistance in 32 isolates strains of MTB and drug susceptivity in 25 isolates strains of MTB by PCR SSCP.Results Among 32 multidrug resistant isolates strains of MTB,28、19、23 isolates had very different rpoB、KatG、rpsL gene mutation pattern of PCR SSCP compared with that of the reference strain (H ₃₇ Rv),and drug susceptivity in 25 isolates had the same PCR SSCP pattern.Compared with drug sensitive test,sensitivity to detecting rpoB、KatG、rpsL genes by PCR SSCP was 87.5%,59.3%,71.9% respectively,and specificity was 100%.Conclusion PCR SSCP is a sensitive and specific method for rapid detecting rpoB、KatG、rpsL genes mutations of MTB,and useful in rapid detecting the multidrug resistant MTB.

Key words: Mycobacterium tuberculosis(MTB), Drug resistance, rpoB、KatG、rpsL gene, PCR-SSCP

HUANG Si yi,QIU Wang long,PAN Zhi ling,et al.. Rapid detecting of the genomic mutations of the multidrug-resistant Mycobacterium tuberculosis by polymerase chain reaction-single strand conformational polymorphism[J]. Chinese Journal of Antituberculosis, 2001, 23(6): 341-343.

References

[1] Hunt J M. Roberts G D,Stockman L,et al. Detection of a genetic lo-cus encoding resistance to rifampin in mycobacterial caters and in clinical specimens [J]. Diagn Microbiol Infect Dis, 1994,18:219～227.
[2] Robert C. Cooksey, P Morlock, et al. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberclosis isolates from patients in New York city [J]. Antimicrob Agent Chemother,1996,40:1186～1188.
[3] Sheldon M, Gil Han Bai,Phillip Sufiys, et al. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuber-culosis [J]. Drug Resistance in M. tuberculosis, 1995, 171:954～960.
[4] Gonzalez N, Jtorres M，Aznar J C，et al.Molecular analysis of rifampin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in Seville [J].Spain Tubercle and LungDisease,1999,79(3)：187～190.
[5] Hedaki 0, Hironbu K,Shigeru K,et al. Relationshop between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosisstrains iso-lated in Japan [J].Antimicrob Agent Chemother, 1996,40(4)：1053～1056.
[6] Amalio T,Paul I,Francine M,et al. Detection of rifampicin-tesistance mutations in Mycobacterium tuberculosis[J].The Lancet, 1993,341:647～650.
[7] Walter H H, Kathrin S, Jeanette B,et al.Molecular analysis of gene mutations in strains of Mycobacterium tuberculosiscomplex from Africa [J] .Antimicrob Agent Chemother, 1997,41(7):1601～1603.
[8] Sriand S,Xipan, Kathrye S,et al. Characterization of rpsL and its mu-tations in steptpmycin resistant Mycobacterium tubercuiosis isolates from diverse geographic localities [J].Antimicrob Agent Chemother,1996,40(4)：1048～1049.
[9] 张宗德，马玙，程绍基，等.异烟肼耐药与结核分支杆菌KatG基因突变的研究[J].中华结核与呼吸杂志，1996,19(6):346～348.
[10] 吴雪琼,庄玉辉，何秀云，等.结核分支杆菌耐药基因的检测[J].中华结核与呼吸杂志，1996,19(6):342～345.
[11] 闫国蕊，刘国华，刘传玉，等.PCR-SSCP技术快速检测结核分支杆菌rpoB基因突变的研究[J].中国防痨杂志，2000,22(3)134～136.
[12] 庄玉辉，何秀云，张小刚，等.耐利福平结核分支杆菌耐药分子机制的研究.中国防痨杂志[J].2000，22(S):1～3.

[1]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[2]	Yang Ziyi, Chen Suting. Research progress on bedaquiline resistance and drug resistance diagnosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 374-379.
[3]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[4]	Xu Zian, Pu Feifei, Feng Jing, Xia Ping. Research progress of high-throughput sequencing technology in the diagnosis and treatment of osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 224-230.
[5]	Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong. Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055.
[6]	Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076.
[7]	Yang Liangzi, Zhang Peize, Lu Shuihua. Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876.
[8]	Xue Yi, Liang Qian, Qi Haoran, Liang Ruixia, Huang Hairong. Reliability analysis of rifampicin-resistance detected by different diagnostics as a predictor for multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 892-896.
[9]	Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei. Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950.
[10]	Gao Lei, Liang Yaxue, Liu Shengsheng, Wang Hua. Analysis of treatment outcomes and influencing factors in 144 elderly patients with rifampicin drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 799-807.
[11]	Zhang Hongtai, Ren Yixuan, Hu peilei, Wang Nenhan, Li Jie, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Li Chuanyou. Comparison of microbiota diversity in the sputum of pulmonary tuberculosis patients with rifampicin resistance or sensitivity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 625-633.
[12]	Du Yuhua, Feng Yajuan, Lei Yu, Lai Keng, He Weiyun. Analysis of the detection and treatment of rifampicin-resistant pulmonary tuberculosis patients in Guangzhou during the “12th Five-Year Plan” and “13th Five-Year Plan” periods [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 678-686.
[13]	Ye Xinchun, Liu Saiduo, Cheng Fang, Jiang Xiangao, Ning Hongye, Wu Zhengxing, Zhou Yueying, Qiu Chaochao, Pan Ning, Shi Jichan. Risk factors of latent tuberculosis infection among close contacts of drug-resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 525-530.
[14]	Bao Xundi, Liang Suo, Li Jun, Ye Qian, Wu Dandan, Wang Shu, LI Yue, Ding Yunsheng, Liu Jie. Analysis of Mycobacterium tuberculosis drug resistance monitoring in Anhui Province from 2016 to 2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 531-537.
[15]	Pei Shaojun, Ou Xichao. Interpretation of the World Health Organization’s Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (2nd Edition) [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 260-266.